Obagi Medical’s Four-Acid Peel Pads Signal a Shift in How Practitioners Approach At-Home Resurfacing

Skincare brand Obagi Medical has launched the CLENZIDERM M.D. Resurfacing Multi-Acid Peel Pads, a practitioner-channel product now available through UK aesthetic distributor Healthxchange, according to a report published by Aesthetics Journal on 7 October 2026. The launch is notable not simply as another exfoliant entry, but because it brings four chemically distinct acids into a single at-home format designed to be recommended and overseen by aesthetic practitioners rather than purchased off the shelf.

Four Acids, One Format: What the Formula Actually Contains

The pads combine glycolic acid (4%), phytic acid (3%), salicylic acid (2%) and mandelic acid (1%) — a quartet that spans AHA, BHA and chelating-acid categories. According to Obagi Medical, the formula is intended to resurface skin, refine pores and address the appearance of fine lines and discoloration. Niacinamide is also included, with the stated aim of reducing visible redness and supporting the skin barrier alongside active exfoliation.

The physical format is a dual-sided lyocell pad, with differing textures designed to allow what the company describes as customisable exfoliation. The product is recommended for evening use, two to three times weekly or as tolerated, following cleansing — a usage pattern consistent with how practitioners typically introduce at-home acids after a professional resurfacing treatment.

The formulation is designed for normal-to-oily and combination skin types, with a particular focus on blemish-prone and uneven skin.

Why the Multi-Acid Approach Is Gaining Traction in Clinical Channels

Single-acid exfoliant formats — a glycolic toner here, a salicylic wash there — have been a retail-channel staple for years. What distinguishes this launch is the deliberate stacking of acids with complementary but mechanically different actions, positioned through a practitioner distributor rather than directly to consumers.

Simone Shoffman, clinical and educational director at Healthxchange, commented in the Aesthetics Journal report: “The combination of four complementary acids provides a targeted approach to exfoliation, addressing multiple pathways associated with blemish-prone skin, while the clinical data demonstrates measurable improvements in texture, breakouts, brightness and pore appearance. It’s an exciting development for practitioners looking to support more comprehensive at-home skin management.”

The reference to clinical data is attributed to Obagi Medical and Healthxchange. Independent verification of specific outcomes is not available from the supplied sources.

The Practitioner-Channel Model and Its Relevance to Asian Aesthetic Markets

Obagi Medical distributes through licensed aesthetic and medical channels rather than mass retail — a model that has established traction in markets including Singapore, Hong Kong and parts of Southeast Asia, where prescription-adjacent skincare and clinic-recommended home-use products have grown consistently alongside in-clinic treatment uptake. The practitioner-channel model matters in this context because it positions multi-acid home exfoliants as adjuncts to professional treatment plans rather than standalone consumer purchases, which aligns with how many aesthetic clinics across the region now structure their patient care protocols.

The supplied sources do not confirm an Asian distribution agreement for this specific product. The current confirmed distribution is through Healthxchange in the UK. However, Obagi Medical’s existing international presence in Asian markets means the launch is relevant context for practitioners and consumers in the region who follow the brand’s clinical-channel pipeline.

What Distinguishes This From Existing At-Home Acid Products

Several factors separate the CLENZIDERM M.D. pads from broadly available consumer exfoliants:

• Acid diversity: Glycolic, phytic, salicylic and mandelic acids each act via different mechanisms — respectively, AHA surface exfoliation, antioxidant-assisted pigment chelation, BHA follicular penetration, and gentler AHA action suited to sensitive or darker skin tones.
• Barrier support built in: The inclusion of niacinamide within an exfoliant format acknowledges a common clinical concern — that repeated acid use without barrier support can increase sensitivity. This combination in one product reduces the risk of patients skipping a separate barrier step.
• Practitioner-channel positioning: Availability through Healthxchange means the product is distributed via trained aesthetic professionals, not as an unsupervised retail purchase.
• Textured dual-sided format: The lyocell pad with differentiated sides is designed to allow practitioners to guide patients on adjusting the intensity of physical and chemical exfoliation at home.

What to Watch as Multi-Acid Formats Develop

The CLENZIDERM M.D. Resurfacing Multi-Acid Peel Pads reflect a broader directional shift in clinical skincare: the integration of multi-functional actives into at-home maintenance products that complement rather than replace in-clinic treatments. For practitioners, the question is whether combining four acids at relatively modest individual concentrations delivers clinically relevant outcomes beyond what a single higher-concentration acid would achieve — a point Shoffman’s comments gesture toward but which the supplied sources do not fully address with independent outcome data.

For Asian markets specifically, the mandelic acid component is worth noting: mandelic acid is increasingly referenced in clinical discussions around exfoliation for deeper skin tones, given its larger molecular size and reportedly lower irritation profile compared to glycolic acid. As Asian aesthetic clinics continue to expand their at-home product offerings for skin of colour, formulations that include mandelic acid alongside barrier-supporting ingredients could become a more significant category focus.

Whether Obagi Medical extends this product’s distribution into Asian markets through its existing professional channels — and whether independent clinical evaluations emerge to support the outcomes cited at launch — are the concrete developments worth tracking from here.

Photo by Poko Skincare on Unsplash